<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471066</url>
  </required_header>
  <id_info>
    <org_study_id>14 7311 02</org_study_id>
    <nct_id>NCT02471066</nct_id>
  </id_info>
  <brief_title>rTMS Effect in Functional Psychogenic Movement Disorders Applied Alone Then Combined With Hypnotherapy</brief_title>
  <acronym>MOVHYSTIM</acronym>
  <official_title>Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Functional Psychogenic Movement Disorders Followed by a Feasibility Study of a Hypnotherapy Treatment as Adjuvant Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of functional psychogenic movement disorders (FNPMD) is challenging for
      neurologists and psychiatrists and only comprehensive multidisciplinary treatment programme
      can be worthwhile for these patients (Moene et al 2002). Recent functional magnetic resonance
      imaging studies have demonstrated abnormalities in motor control at cortical level,
      hyperactivity of limbic system and disturbance of connectivity between these two systems
      leading to a lack of self-agency, (Voon et al 2010,2011).Two recent studies suggested a
      possible therapeutic effect of transcranial magnetic stimulation (TMS) in FNPMD (Dakotakis
      2011, Garcin, 2013).

      In this protocol our objectives are twofold :

        1. to compare the effect of 5 consecutive daily sessions of rTMS on FNPMD in a double-blind
           randomized controlled study

        2. to study the effect of 3 weekly hypnosis sessions combined with rTMS in FNPMD
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Psychogenic Movement Disorder Rating Scale (PMDRS= Hinson score between baseline and one month after rTMS treatment</measure>
    <time_frame>Inclusion and 1 month later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity scale (CGI-SEVERITY/CGI-I/CGI-S)</measure>
    <time_frame>inclusion, inclusion + 5 days, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HAD/HDRS)</measure>
    <time_frame>inclusion, inclusion + 1 month, inclusion + 6 months, inclusion + 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (SF-36)</measure>
    <time_frame>inclusion, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperament and Character Inventory (TCI)</measure>
    <time_frame>inclusion, inclusion + 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scale (VAS)</measure>
    <time_frame>: inclusion, inclusion + 5 days, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Movement Disorders</condition>
  <arm_group>
    <arm_group_label>active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 patients will be enrolled in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>12 patients will be enrolled in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <description>Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham
Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session</description>
    <arm_group_label>active rTMS</arm_group_label>
    <arm_group_label>sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Man or woman with FNPMD for at least 2 months, diagnosed from clinical Diagnostic and
             Statistical Manual V conversive somatoform troubles and Gupta &amp; Lang (2009) and
             Edwards &amp; Bahtia 2012 neurological clinical criteria

        Exclusion criteria:

          -  Severe progressive psychiatric disorders

          -  Cardiac pace-maker

          -  Metallic prosthesis

          -  Cochlear implants

          -  Previous neurosurgery

          -  Epilepsy

          -  Severe cardiac disease

          -  -Alcohol or toxic abuse for the last 12 months

          -  Drugs such clozapine, bupropion, methadone or theophylline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion SIMONETTA-MOREAU, MD</last_name>
    <phone>561 779 490</phone>
    <phone_ext>33</phone_ext>
    <email>simonetta.m@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine VERNET</last_name>
      <phone>5.61.77.72.16</phone>
      <phone_ext>33</phone_ext>
      <email>vernet.d@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Marion SIMONETTA-MOREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Dafotakis M, Ameli M, Vitinius F, Weber R, Albus C, Fink GR, Nowak DA. [Transcranial magnetic stimulation for psychogenic tremor - a pilot study]. Fortschr Neurol Psychiatr. 2011 Apr;79(4):226-33. doi: 10.1055/s-0029-1246094. Epub 2011 Apr 8. German.</citation>
    <PMID>21480152</PMID>
  </reference>
  <reference>
    <citation>Garcin B, Roze E, Mesrati F, Cognat E, Fournier E, Vidailhet M, Degos B. Transcranial magnetic stimulation as an efficient treatment for psychogenic movement disorders. J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):1043-6. doi: 10.1136/jnnp-2012-304062. Epub 2013 Feb 5.</citation>
    <PMID>23385844</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

